[Adverum Biotechnologies, Inc.] Adverum Biotechnologies, Inc. announced that the first patient was dosed in Cohort 4 of the ongoing OPTIC Phase I clinical trial for ADVM-022 for the treatment of wet age-related macular degeneration (AMD).
[Nature Technology Feature] When reports emerged in late 2019 of an outbreak of a new coronavirus centred in Wuhan, China, researchers at the virological-analysis website Nextstrain were ready. The open-source project tracks the spread of viruses through genetic variations in the sequences that scientists find.
[STAT News] Rick Bright, one of the nation’s leading vaccine development experts and the director of the Biomedical Advanced Research and Development Authority, is no longer leading the organization.
[Expert Review of Clinical Immunology] Scientists explore the role of Tregs in the immune system, delve into their contribution to cancer and tumor progression, and highlight therapeutic strategies targeting Tregs, along with innovative delivery systems.
[Cell Research] Researchers unveiled a mechanism for V-domain Ig suppressor of T cell activation (VISTA) regulation in T cells and highlights targeting tripartite motif containing 25 (TRIM25)–VISTA as a potential strategy to enhance tumor immunotherapy.
[Leukemia] The authors conducted integrated genome-wide CRISPR-Cas9 loss-of-function screens using CD30-specific CAR-engineered NK cells, alongside a complementary PD-L1 regulator screen, and uncovered a critical role for interleukin-1 receptor signaling in modulating CAR therapy efficacy in both ALK⁺ and ALK⁻ anaplastic large cell lymphoma.